Uncategorized
Mimetogen initiates phase 3 trial for dry eye syndrome therapy
Mimetogen Pharmaceuticals has begun enrolling patients in a pivotal phase 3 clinical study of an ophthalmic solution for the treatment of dry eye syndrome, according to a press release.MIM-D3 ophthalmic solution is the first in a class of molecules called TrkA agonists, the release said. It stimulates the production of mucin, which plays a role in the protection and health of the ocular surface, and it may have further benefits, such as improving neural function, which may improve corneal sensitivity and integrity.